Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Thiogenesis Therapeutics Corp. announced its CEO will present at the 3rd Annual Leigh Syndrome Symposium, discussing TTI-0102, a potential treatment for Leigh syndrome and MELAS. The compound aims to combat mitochondrial oxidative stress by increasing glutathione levels, with Phase 2 clinical trials anticipated soon.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
